<i>In vitro</i> activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains
NOSO-502 showed potent in vitro inhibitory and bactericidal activity against a panel of Enterobacterales enriched for resistant phenotypes for which there are few therapeutic choices. These findings need to be placed in context with the appropriate pharmacokinetic and dynamic characteristics of NOSO-502.
Authors
- Maxime Gualtiéri (ORCID: https://orcid.org/0000-0001-6590-2468)
- Pippa Griffin
- Alasdair MacGowan (ORCID: https://orcid.org/0000-0002-6720-5268)
- Emilie Racine (ORCID: https://orcid.org/0000-0002-4265-9669)
- Marie Attwood (ORCID: https://orcid.org/0000-0003-1047-2098)
- Alan Noel
Institutions
- Southmead Hospital (GB)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1093/jac/dkaf152
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.59